← Back to Search

Virus Therapy

VDMN-21 Patch for Warts

Phase 2
Recruiting
Research Sponsored by Veradermics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Subject is a male or non-pregnant female, 18 to 65 years of age
Females must be post-menopausal, surgically sterile, or use an effective method of birth control. Women of childbearing potential (WOCBP) must have a negative urine pregnancy test (UPT) at Visit 1/Baseline
Must not have
Subject used or will use oral zinc and/or cimetidine within 30 days prior to enrollment or during the course of the study
Subject has received 3 or more prior treatments to the Target Lesion without resolution
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline up to day 134
Awards & highlights

Summary

This trial tests the safety and effectiveness of the VDMN-21 patch for treating warts. It includes people with common warts that are difficult to treat. The patch works by applying medicine directly to the wart to help get rid of it.

Who is the study for?
This trial is for adults aged 18-65 with 1 to 8 common warts. Participants must be in good health, not pregnant, and willing to follow the study plan including telehealth visits. They can't have used certain wart treatments recently or be on immunosuppressive therapy, and they shouldn't have a history of significant eye inflammation or active cancer (except non-melanoma skin cancer).
What is being tested?
The trial tests two doses of VDMN-21 Patch against a placebo patch to see if they're safe and effective for treating common warts. Participants will receive repeated treatment sessions with one of these patches.
What are the potential side effects?
While specific side effects are not listed here, participants may experience reactions at the site where the patch is applied such as redness, itching, or irritation. Systemic side effects could occur depending on how the body absorbs ingredients from the patch.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 18 and 65 years old and not pregnant.
Select...
I am a woman who cannot become pregnant or am using birth control and have a negative pregnancy test.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have taken or will take zinc or cimetidine within 30 days before joining the study or during it.
Select...
I've had 3 or more treatments for my specific cancer area without it getting better.
Select...
I am not currently being treated for any cancer except nonmelanoma skin cancer.
Select...
I have had serious eye inflammation, like uveitis.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline up to day 134
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline up to day 134 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Proportion of subjects with complete clinical resolution of the Target Lesion at end of treatment period

Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: Treatment Group B (High Dose)Experimental Treatment1 Intervention
High does patch will be applied adjacent to the target wart and remain in place for 5 minutes then removed. There may be up to 6 treatments (approximately 1 per month).
Group II: Treatment Group A (Low Dose)Experimental Treatment1 Intervention
Low does patch will be applied adjacent to the target wart and remain in place for 5 minutes then removed. There may be up to 6 treatments (approximately 1 per month).
Group III: Treatment Group C (Vehicle)Placebo Group1 Intervention
Vehicle patch will be applied adjacent to the target wart and remain in place for 5 minutes then removed. There may be up to 6 treatments (approximately 1 per month).

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for warts include topical agents like salicylic acid, which works by exfoliating the infected skin and promoting immune response; cryotherapy, which involves freezing the wart tissue to cause cell destruction; and immunotherapy, which stimulates the body's immune system to attack the wart-causing virus. Understanding these mechanisms is crucial for patients as it helps them comprehend how the treatments work, the expected outcomes, and potential side effects, enabling informed decisions about their care.

Find a Location

Who is running the clinical trial?

Veradermics, Inc.Lead Sponsor
1 Previous Clinical Trials
20 Total Patients Enrolled

Media Library

VDMN-21 Patch (Virus Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT05799157 — Phase 2
Warts Research Study Groups: Treatment Group C (Vehicle), Treatment Group A (Low Dose), Treatment Group B (High Dose)
Warts Clinical Trial 2023: VDMN-21 Patch Highlights & Side Effects. Trial Name: NCT05799157 — Phase 2
VDMN-21 Patch (Virus Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05799157 — Phase 2
~14 spots leftby Dec 2024